Development status: Experimental

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: Active against <i>Enterococcus faecalis</i>, <i>Salmonella typhimurium</i>, and uropathogenic <i>Escherichia coli</i>

Additional information: Synthetic compound; approved by FDA as chemotherapeutic drug for treating chronic myelogenous leukaemia; a repurposed drug; does not have an intrinsic antibacterial effect but enhances macrophage clearance of bacterial infection